Funding for this research was provided by:
Biobanking and BioMolecular resources Research Infrastructurey
Trolle-Wachtmeister Foundation for Medical Research
European Union Interreg programme IV A.
Received: 2 June 2020
Accepted: 16 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: The study was approved by the Regional Ethical Committee in Lund, Sweden, with reference numbers DNR 2015/267 and DNR 2017/802. An opt-out procedure made a withdrawal of participation possible.
: Not applicable.
: OL, ML, MS, MA, HL, AF and HF declare that they have no competing interests, no financial or any other interests in SphingoTec GmbH and have not been in any way influenced by SphingoTec GmbH in writing this research paper. OM is listed as an inventor on a patent on bio-ADM in dementia prediction. SphingoTec GmbH is the owner of the patent. DB and JS are employed by SphingoTec GmbH and participate in the company’s employee stock option program. Bioactive ADM was analysed free of charge by SphingoTec GmbH, Neuendorfstrae 15A, 16761 Hennigsdorf, Germany.